Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16087811 | 0.91 | RXRA (0.35) | RXRAGRIN1GRIN2BNOTUMNR1H2 | |
| SCHEMBL19001249 | 0.81 | MAPT (0.38) | RXRAGRIN1GRIN2BNOTUMHSD11B1 | |
| SCHEMBL19000982 | 0.81 | MAPT (0.38) | RXRAGRIN1GRIN2BNOTUMHSD11B1 | |
| SCHEMBL16088325 | 0.81 | PDE4B (0.36) | NOTUMNR1H2NR1H3ALOX5AP | |
| SCHEMBL19012623 | 0.80 | MAPT (0.42) | — | |
| SCHEMBL22699598 | 0.80 | RXRA (0.43) | RXRAGRIN1GRIN2BNOTUMNR1H2 | |
| SCHEMBL19001075 | 0.80 | MAPT (0.42) | — | |
| SCHEMBL16683838 | 0.77 | ALOX5AP (0.40) | NOTUMNR1H2NR1H3ALOX5AP | |
| SCHEMBL19069991 | 0.77 | NR1H2 (0.36) | NOTUMNR1H2NR1H3ALOX5AP | |
| SCHEMBL21718972 | 0.77 | MAPT (0.41) | RXRAGRIN1GRIN2BAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695149-B2 | 1,2,6-substituted benzimidazoles as flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-04 | — | — | US | disclosed |
| US-8952177-B2 | 1,2,6-substituted benzimidazoles as FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-10 | — | — | US | disclosed |
| US-20140275029-A1 | 1,2,6-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275029-A1 | 1,2,6-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | FEN1, FOXM1, F12 | RXRA 1620/4885GRIN1 1360/4885GRIN2B 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.